Skip to main content
SpringerLink
Log in

Bupropion modified/extended release: a guide to its use in major depressive disorder

  • Drug and Profile Report
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1

References

  1. Dhillon S, Yang LP, Curran MP. Bupropion: a review of its use in the management of major depressive disorder [published erratum appears in Drugs 2008; 68 (7): 980]. Drugs 2008; 68(5): 653–89

    Article  PubMed  CAS  Google Scholar 

  2. American Psychiatric Association. Mood disorders. In: Diagnostic and statistical manual of mental disorders. 4th ed. text revisions. Washington, DC: American Psychiatric Association, 2000: 345–428

  3. Üstün TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004 May; 184: 386–92

    Article  PubMed  Google Scholar 

  4. Holtzheimer III PE, Nemeroff CB. Advances in the treatment of depression. NeuroRx 2006 Jan; 3(1): 42–56

    Article  PubMed  CAS  Google Scholar 

  5. Heads of Medicines Agencies. Wellbutrin XR: summary of product characteristics [online]. Available from URL: http://db.cbg-meb.nl/mri/spc/nlh-0785-001-002.pdf [Accessed 2008 Mar 4]

  6. Wellbutrin XL® (bupropion extended-release tablets): US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2007 Aug

  7. GlaxoSmithKline. A two-way, crossover, steady state, multipledose, open-label, fasting, comparative bioavailability study of bupropion HCl 300 mg extended release tablets (1 × 300 mg once daily, q.d.) versus Wellbutrin 100 mg tablets (t.i.d.) in normal healthy non-smoking male and female subjects (study no. AK1BIOVAL2544) [online]. Available from URL: http://ctr.gsk.co.uk [Accessed dy2008 Jun 27]

  8. Jefferson JW, Rush AJ, Nelson JC, et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006 Jun; 67(6): 865–73

    Article  PubMed  CAS  Google Scholar 

  9. Thase ME, Clayton AH, Chrzanowski W, et al. Bupropion extended release and venlafaxine extended release for the treatment of depression: results from three multicenter trials [abstract no. 146 plus poster]. 14th Congress of Psychiatry of the Association of European Psychiatrists; 2006 Mar 4–8; Nice

  10. Clayton AH, Croft HA, Horrigan JP, et al. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry 2006 May; 67(5): 736–46

    Article  PubMed  CAS  Google Scholar 

  11. Thase ME, Clayton AH, Haight BR, et al. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol 2006 Oct; 26(5): 482–8

    Article  PubMed  CAS  Google Scholar 

  12. Hewett K, Chrzanowski W, Rousseau R, et al. Efficacy and safety of bupropion XL in elderly patients with major depressive disorder [abstract no. P.2.c.006 plus poster]. Eur Neuropsychopharmacol 2006; 16Suppl. 4: S315–16

    Google Scholar 

  13. GlaxoSmithKline. A twelve-week, multi-center, randomized, double-blind, double-dummy, parallel-group, active-controlled, escalating dose study to compare the effects on sexual functioning of bupropion hydrochloride extended-release (WELLBUTRIN® XL, 150-450 mg/day) and extended-release venlafaxine (Effexor XR, 75–225 mg/day) in subjects with major depressive disorder (study No. WELL 100368) [online]. Available from URL: http://ctr.gsk.co.uk [Accessed 2007 Dec 18]

  14. GlaxoSmithKline. A multi-centre, randomised, double-blind, parallel-group, placebo- and active-controlled, flexible-dose study evaluating the efficacy, safety and tolerability of extended-release bupropion hydrochloride (150mg–300mg once daily), extended-release venlafaxine hydrochloride (75mg–150mg once daily) and placebo in subjects with major depressive disorder (study no. AK130939) [online]. Available from URL: http://ctr.gsk.co.uk/ [Accessed 2007 Dec 18]

  15. GlaxoSmithKline. A multi-centre, randomised, double-blind, parallel-group, placebo- and active-controlled, flexible dose study evaluating the efficacy, safety and tolerability of extended-release bupropion hydrochloride (150mg–300mg once daily), extended-release venlafaxine hydrochloride (75mg–150mg once daily) and placebo in subjects with major depressive disorder (study No. WXL101497) [online]. Available from URL: http://ctr.gsk.co.uk [Accessed 2007 Dec 18]

  16. Croft HA, Wightman D, Hewett K, et al. Additional data on the safety and tolerability of bupropion extended-release: newly accumulated data extends previous findings in placebo controlled clinical trials [abstract no. NR484 plus poster]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto (ON)

  17. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002 Apr; 63(4): 357–66

    Article  PubMed  Google Scholar 

  18. Papakostas GI. Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram [commentary]. Evid Based Ment Health 2006 Nov; 9(4): 100

    Article  PubMed  Google Scholar 

  19. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000 Apr; 157Suppl. 4: 1–45

    Google Scholar 

  20. Mann JJ. The medical management of depression. N Engl J Med 2005; 353(17): 1819–34

    Article  PubMed  CAS  Google Scholar 

  21. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical practice guideline 23. London: National Institute for Clinical Excellence, 2004

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bupropion modified/extended release: a guide to its use in major depressive disorder. Drugs Ther. Perspect 25, 1–4 (2009). https://doi.org/10.2165/0042310-200925010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0042310-200925010-00001

Search

Navigation